| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000031091 |
| Receipt No. | R000035510 |
| Official scientific title of the study | The effect of DAAs therapy for patients with HCV infection on prognosis and incidence of HCC |
| Date of disclosure of the study information | 2018/01/31 |
| Last modified on | 2018/01/31 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | The effect of
DAAs therapy for patients with HCV infection on prognosis and incidence of HCC |
|
| Title of the study (Brief title) | Effect of DAAs on incidence of HCC and prognosis | |
| Region |
|
|
| Condition | ||
| Condition | Patients with HCV infection | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To analyze the effect of
DAAs therapy for HCV infected patients on HCC incidence,risk maker of incidence of HCC and prognosis |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To investigate incidence of HCC and
prognosis after HCV eradication. To analyze risk factor of those |
| Key secondary outcomes | 1 HCC incidence and prognosis in HD patients with HCV infection.
To compare HCC incidence and prognosis between patient with or without IFN-therapy 2 To investigate change in ALT and AFP 3 To investigate the change in liver fibrosis and steatosis after SVR 4 To investigate the change in lipid/glucose/Fe metabolismafter SVR 5 To investigate the rate of Hospitalization due to liver disease |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | HCV infected patients who were treated and achieved SVR between 2011 and 2026 | |||
| Key exclusion criteria | 1) Patients with difficult-to-control heart disease
2) Other patients judged to be inappropriate to participate in the study by the primary physician |
|||
| Target sample size | 400 | |||
| Research contact person | |
| Name of lead principal investigator | Goki Suda |
| Organization | Graduate School of Medicine,
Hokkaido University |
| Division name | Department of Gastroenterology and Hepatology |
| Address | North 15, West 7, Kita-ku, Sapporo, Hokkaido |
| TEL | 011-716-2111 |
| gsudgast@pop.med.hokudai.ac.jp | |
| Public contact | |
| Name of contact person | Goki Suda |
| Organization | Graduate School of Medicine, Hokkaido University |
| Division name | Department of Gastroenterology and Hepatology |
| Address | North 15, West 7, Kita-ku, Sapporo, Hokkaido |
| TEL | 011-716-2111 |
| Homepage URL | |
| gsudgast@pop.med.hokudai.ac.jp | |
| Sponsor | |
| Institute | Graduate School of Medicine, Hokkaido University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Graduate School of Medicine, Hokkaido University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | 1) patients background
2) blood count 3) biochemical examination 4) tumor maker 5) HCV RNA, RAV 6) glucose, lipid metabolism 7) fibrosis maker 8) radiological exmamination 9) concomitant drug 10) admission due to liver disease 11) micro RNA 12) microbiota |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035510 |